Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.11 USD

44.11
15,765,101

-0.44 (-0.99%)

Updated May 16, 2024 04:00 PM ET

Pre-Market: $44.16 +0.05 (0.11%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Arpita Dutt headshot

3 Key Factors to Look Out for in Biogen's Q1 Results

With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

    Arpita Dutt headshot

    Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

    Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

      Is J&J's Pharma Sales Slowdown a Warning for Other Players?

      Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

        Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

        Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

          Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

          Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

            5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

            2017 is expected to be a strong year for drug stocks.

              Biogen to License Alzheimer Candidate from Bristol-Myers

              Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

                J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

                We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

                  Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

                    Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

                    Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.

                      AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                      AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

                        Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

                        We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

                          Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

                          Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

                            5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

                            Lily carries a Zacks Rank #2 (Buy).

                              Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

                              Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

                                Bristol-Myers (BMY), Incyte to Advance Clinical Program

                                Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

                                  Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

                                  Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.

                                    Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

                                    Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

                                      This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

                                        Infinity Pharma Focuses on Cancer Drug: Competition Looms

                                        We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

                                          Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

                                          Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

                                            6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

                                            Glaxo carries a Zacks Rank #2 (Buy).

                                              Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                                              Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                                                Sweta Killa headshot

                                                Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

                                                President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

                                                  Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

                                                  Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.